TNF and juvenile idiopathic arthritis: Over the following years, three other anti-tumor necrosis factor (TNF) agents (infliximab [13], adalimumab [14], and golimumab [15]) were tested in RCTs in patients with polyarticular course with JIA and a trial with another TNF-blocking agent (certolizumab pegol) is currently being performed [16].